The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)

In recent years immunomodulators have gained a strong interest and represent nowadays an active expanding area of research for the control of microbial diseases and for their therapeutic potential in preventing, treating and reducing the morbidity and mortality of different diseases. Pidotimod (3-L-...

Full description

Bibliographic Details
Main Authors: Francesca Caccuri, Antonella Bugatti, Silvia Corbellini, Sara Roversi, Alberto Zani, Pietro Mazzuca, Stefania Marsico, Arnaldo Caruso, Cinzia Giagulli
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/20/21/5287
id doaj-309c1043421540c69eccd44e737dff96
record_format Article
spelling doaj-309c1043421540c69eccd44e737dff962020-11-25T02:15:41ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-10-012021528710.3390/ijms20215287ijms20215287The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)Francesca Caccuri0Antonella Bugatti1Silvia Corbellini2Sara Roversi3Alberto Zani4Pietro Mazzuca5Stefania Marsico6Arnaldo Caruso7Cinzia Giagulli8Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, ItalySection of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, ItalyLaboratory of Microbiology and Virology, Azienda Socio Sanitaria Territoriale Spedali Civili, 25123 Brescia, ItalySection of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, ItalySection of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, ItalySection of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, ItalyDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, 87036 Cosenza, ItalySection of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, ItalySection of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, ItalyIn recent years immunomodulators have gained a strong interest and represent nowadays an active expanding area of research for the control of microbial diseases and for their therapeutic potential in preventing, treating and reducing the morbidity and mortality of different diseases. Pidotimod (3-L-pyroglutamyl-L-thiaziolidine-4carboxylic acid, PDT) is a synthetic dipeptide, which possesses immunomodulatory properties and exerts a well-defined pharmacological activity against infections, but its real mechanism of action is still undefined. Here, we show that PDT is capable of activating tyrosine phosphorylation-based cell signaling in human primary monocytes and triggering rapid adhesion and chemotaxis. PDT-induced monocyte migration requires the activation of the PI3K/Akt signaling pathway and chemokine receptor CXCR3. Indeed, a mAb to CXCR3 and a specific receptor inhibitor suppressed significantly PDT-dependent chemotaxis, and CXCR3-silenced primary monocytes lost responsiveness to PDT chemoattraction. Moreover, our results highlighted that the PDT-induced migratory activity is sustained by the CXCR3A isoform, since CXCR3-transfected L1.2 cells acquired responsiveness to PDT stimulation. Finally, we show that PDT, as CXCR3 ligands, is also able to direct the migration of IL-2 activated T cells, which express the highest levels of CXCR3 among CXCR3-expressing cells. In conclusion, our study defines a chemokine-like activity for PDT through CXCR3A and points on the possible role that this synthetic dipeptide may play in leukocyte trafficking and function. Since recent studies have highlighted diverse therapeutic roles for molecules which activates CXCR3, our findings call for an exploration of using this dipeptide in different pathological processes.https://www.mdpi.com/1422-0067/20/21/5287pidotimodcxcr3monocytemigrationpi3k/akt pathwayt cellimmunomodulant
collection DOAJ
language English
format Article
sources DOAJ
author Francesca Caccuri
Antonella Bugatti
Silvia Corbellini
Sara Roversi
Alberto Zani
Pietro Mazzuca
Stefania Marsico
Arnaldo Caruso
Cinzia Giagulli
spellingShingle Francesca Caccuri
Antonella Bugatti
Silvia Corbellini
Sara Roversi
Alberto Zani
Pietro Mazzuca
Stefania Marsico
Arnaldo Caruso
Cinzia Giagulli
The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)
International Journal of Molecular Sciences
pidotimod
cxcr3
monocyte
migration
pi3k/akt pathway
t cell
immunomodulant
author_facet Francesca Caccuri
Antonella Bugatti
Silvia Corbellini
Sara Roversi
Alberto Zani
Pietro Mazzuca
Stefania Marsico
Arnaldo Caruso
Cinzia Giagulli
author_sort Francesca Caccuri
title The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)
title_short The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)
title_full The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)
title_fullStr The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)
title_full_unstemmed The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)
title_sort synthetic dipeptide pidotimod shows a chemokine-like activity through cxc chemokine receptor 3 (cxcr3)
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2019-10-01
description In recent years immunomodulators have gained a strong interest and represent nowadays an active expanding area of research for the control of microbial diseases and for their therapeutic potential in preventing, treating and reducing the morbidity and mortality of different diseases. Pidotimod (3-L-pyroglutamyl-L-thiaziolidine-4carboxylic acid, PDT) is a synthetic dipeptide, which possesses immunomodulatory properties and exerts a well-defined pharmacological activity against infections, but its real mechanism of action is still undefined. Here, we show that PDT is capable of activating tyrosine phosphorylation-based cell signaling in human primary monocytes and triggering rapid adhesion and chemotaxis. PDT-induced monocyte migration requires the activation of the PI3K/Akt signaling pathway and chemokine receptor CXCR3. Indeed, a mAb to CXCR3 and a specific receptor inhibitor suppressed significantly PDT-dependent chemotaxis, and CXCR3-silenced primary monocytes lost responsiveness to PDT chemoattraction. Moreover, our results highlighted that the PDT-induced migratory activity is sustained by the CXCR3A isoform, since CXCR3-transfected L1.2 cells acquired responsiveness to PDT stimulation. Finally, we show that PDT, as CXCR3 ligands, is also able to direct the migration of IL-2 activated T cells, which express the highest levels of CXCR3 among CXCR3-expressing cells. In conclusion, our study defines a chemokine-like activity for PDT through CXCR3A and points on the possible role that this synthetic dipeptide may play in leukocyte trafficking and function. Since recent studies have highlighted diverse therapeutic roles for molecules which activates CXCR3, our findings call for an exploration of using this dipeptide in different pathological processes.
topic pidotimod
cxcr3
monocyte
migration
pi3k/akt pathway
t cell
immunomodulant
url https://www.mdpi.com/1422-0067/20/21/5287
work_keys_str_mv AT francescacaccuri thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT antonellabugatti thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT silviacorbellini thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT sararoversi thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT albertozani thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT pietromazzuca thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT stefaniamarsico thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT arnaldocaruso thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT cinziagiagulli thesyntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT francescacaccuri syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT antonellabugatti syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT silviacorbellini syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT sararoversi syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT albertozani syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT pietromazzuca syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT stefaniamarsico syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT arnaldocaruso syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
AT cinziagiagulli syntheticdipeptidepidotimodshowsachemokinelikeactivitythroughcxcchemokinereceptor3cxcr3
_version_ 1724894583884611584